US regulators seek more information on Teva/Barr deal
This article was originally published in Scrip
Executive Summary
US antitrust regulators have requested additional information in connection with Teva Pharmaceutical Industries' $7.5 billion bid to acquireBarr Pharmaceuticals. The generics firms said they received a second request for information from theFederal Trade Commission. As a result, the Hart-Scott-Rodino waiting period for antitrust clearance will be extended until 30 days after the companies substantially comply with the request. Teva and Barr said they still expect the transaction to close late this year. When the deal was announced in July, a Teva executive predicted that FTC-ordered divestitures could include oral contraceptives and pipeline products.